Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

Now Viewing

EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

• What are your perceptions on efficacy and safety data on PROTAC
  • ASCO 2024 #TPS1131TACTIVE-K: Phase 1b/2 study of vepdegestrant plus CDK4i PF-07220060
• What are your perceptions on efficacy and safety data on SERM:
  • Lasoxifene: ASCO 2024 #TPS1127: Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
• How do these options compare? Why might you choose one of these options vs fulvestrant?